Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
403.15M | 393.41M | 324.24M | 252.48M | 203.00M | 187.51M | Gross Profit |
59.28M | 54.00M | 59.57M | 52.09M | 40.85M | 36.88M | EBIT |
-52.06M | -60.12M | -77.02M | -72.01M | -45.86M | -8.20M | EBITDA |
-46.70M | -50.88M | -70.45M | 8.40M | -7.94M | -11.29M | Net Income Common Stockholders |
-64.36M | -64.66M | -83.07M | 1.66M | -10.93M | -14.32M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
39.74M | 49.67M | 82.86M | 73.81M | 114.30M | 6.00M | Total Assets |
164.00M | 172.72M | 209.24M | 263.75M | 203.44M | 65.69M | Total Debt |
102.31M | 123.15M | 119.67M | 108.18M | 183.00K | 11.93M | Net Debt |
62.57M | 73.48M | 86.19M | 94.17M | -114.12M | 5.93M | Total Liabilities |
158.93M | 169.13M | 152.22M | 139.07M | 99.28M | 37.59M | Stockholders Equity |
5.07M | 3.59M | 57.02M | 124.68M | 104.16M | 28.10M |
Cash Flow | Free Cash Flow | ||||
-19.15M | -30.33M | -40.88M | -67.28M | -35.73M | -685.88K | Operating Cash Flow |
-15.64M | -26.54M | -36.31M | -61.76M | -32.68M | 508.24K | Investing Cash Flow |
26.62M | 46.21M | 62.64M | -131.61M | -12.15M | -8.84M | Financing Cash Flow |
-7.29M | -3.49M | -6.85M | 92.21M | 154.01M | 11.89M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $1.62B | 15.14 | 11.19% | 2.33% | 19.16% | 31.92% | |
68 Neutral | $12.25B | 25.08 | 25.33% | 0.54% | 11.21% | 30.38% | |
64 Neutral | $1.97B | 11.39 | 10.38% | 2.45% | -8.86% | -36.22% | |
60 Neutral | $2.07B | 11.09 | 6.35% | ― | 5.48% | ― | |
59 Neutral | $538.78M | ― | 39.18% | ― | 1.05% | -288.07% | |
55 Neutral | $285.42M | ― | -227.77% | ― | 17.64% | 13.86% | |
53 Neutral | $5.25B | 3.24 | -45.38% | 2.81% | 16.79% | -0.06% |
The Oncology Institute, Inc. has prepared an investor presentation to explore a potential private placement of securities, known as PIPE Financing. The presentation highlights the company’s unique approach in the oncology market, emphasizing its capability to manage population-level care contracts and its focus on reducing patient healthcare costs. The company’s strategy positions it to capitalize on the growing oncology market, driven by factors such as reimbursement misalignment and high-cost drugs.
The most recent analyst rating on (TOI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Oncology Institute stock, see the TOI Stock Forecast page.
On May 7, 2025, The Oncology Institute held its Annual Meeting of Stockholders where three proposals were considered. The stockholders elected eight directors, ratified the appointment of BDO USA, LLP as the independent registered public accounting firm, and approved a proposal to amend the company’s certificate of incorporation to potentially effect a reverse stock split.
On May 2, 2025, Jeremy Castle announced his resignation as Chief Operating Officer of The Oncology Institute, Inc., effective May 30, 2025. His departure was not due to any disagreements with the company regarding its operations, policies, or practices.
The Oncology Institute, Inc. has prepared an investor presentation to discuss a potential private placement of securities (PIPE Financing). The presentation is intended for qualified institutional buyers and accredited investors, emphasizing confidentiality and disclaiming any offer or solicitation of securities. The company highlights its unique market position and the significant growth potential in the oncology sector, driven by complex clinical pathways and high-cost drugs. The Institute’s integrated approach aims to reduce patient healthcare costs and improve access to cutting-edge treatments.